← All trials
NCT04885634
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Jan 31, 2024
- Completion date
- Nov 30, 2024
- First posted
- May 13, 2021
- Last posted
- May 18, 2021
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Odense University HospitalLead sponsor
- University of CopenhagenStudy director
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of Southern DenmarkSponsor investigator
- University of Southern DenmarkStudy director
- Hospital of South West JutlandCollaborator
- Svendborg HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.